Table 1

Demographics and baseline disease characteristics for responders versus non-responders to galcanezumab

Responders
(≥50% reduction)
Non-responders
Baseline parametersGalcanezumab
(n=46)
Placebo
(n=26)
Galcanezumab
(n=53)
Placebo
(n=79)
Age, years*42±1237±1241±1144±11
Gender, female, n (%)38 (83)23 (88)44 (83)69 (87)
Number of MHD*6±27±27±37±3
Number of MHD or probable MHD*8±29±39±38±3
  • *Values presented as mean±SD.

  • MHD, migraine headache days.